Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 135

Sort by

Sort Order Select

Journal Articles

Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panos Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Dr, Foteini Theodorakakou, Vasiliki Spiliopoulou, Irene Solia, Evangelos Eleutherakis-Papaiakovou, Giorgos Psarros, Efstathios Kastritis, Meletios A Dimopoulos

Blood blood.2025031629.

https://doi.org/10.1182/blood.2025031629

Published: 2025

Includes: Supplemental data

Journal Articles

Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens

Efstathios Kastritis, Eirini Solia, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Despina Fotiou, Stavroula Giannouli, Panagiotis Tsirigotis, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2228.

https://doi.org/10.1182/blood-2025-2228

Published: 2025

Journal Articles

Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement

Efstathios Kastritis, Eirini Solia, Ilias Katsadouros, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2227.

https://doi.org/10.1182/blood-2025-2227

Published: 2025

Journal Articles

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

Panagiotis Malandrakis, Ioannis Kostopoulos, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Sotirios Manganas, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Vasiliki Spiliopoulou, Magdalini Migkou, Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania Tsitsilonis, Meletios Dimopoulos, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 2216.

https://doi.org/10.1182/blood-2025-2216

Published: 2025

Journal Articles

Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies

Foteini Theodorakakou, Zoey Kapsimali, Alexandra Papadimou, Katerina Chrisostomidou, Kostantina Taouxi, Ilias Katsadouros, Panagiotis Malandrakis, Magdalini Migkou, Eirini Solia, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Evangelos Eleutherakis Papaiakovou, Asimina Papanikolaou, Maria Gavriatopoulou, Evangelos Terpos, Eleni Pergantou, Meletios Dimopoulos, Ioannis Papassotiriou, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 2192.

https://doi.org/10.1182/blood-2025-2192

Published: 2025

Journal Articles

Characteristics and clinical course of younger Patients with early lesions in a contemporary cohort of 1240 patients: Low risk features and low risk of complications

Eirini Solia, Foteini Theodorakakou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Konstantinos Giannakas, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 2191.

https://doi.org/10.1182/blood-2025-2191

Published: 2025

Journal Articles

Management and long-term hematologic and neurologic outcomes of IgM-related neuropathy: A single center experience

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Sotirios Manganas, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Eirini Solia, Evangelos Eleutherakis-Papaiakovou, Ilias Katsadouros, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Terpos, Efstathios Kastritis, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2184.

https://doi.org/10.1182/blood-2025-2184

Published: 2025

Journal Articles

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

Efstathios Kastritis, Maria Gavriatopoulou, Foteini Theodorakakou, Eirini Solia, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Despina Fotiou, Konstantinos Giannakas, Erasmia Boutakoglou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 923.

https://doi.org/10.1182/blood-2025-923

Published: 2025

Journal Articles

The novel ims / IMWG high-risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis

Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Eirini Solia, Evangelos Eleutherakis-Papaiakovou, Ilias Katsadouros, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Erasmia Boutakoglou, Konstantinos Giannakas, Evangelos Terpos, Meletios Dimopoulos, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 3986.

https://doi.org/10.1182/blood-2025-3986

Published: 2025

Journal Articles

Efficacy and safety of recombinant adjuvanted zoster vaccine in patients with monoclonal gammopathies: A prospective study

Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Eirini Solia, Ilias Katsadouros, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Terpos, Efstathios Kastritis, Meletios Dimopoulos, Maria Gavriatopoulou

Blood (2025) 146 (Supplement 1): 3985.

https://doi.org/10.1182/blood-2025-3985

Published: 2025

Journal Articles

Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Study

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Eirini Solia, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Ilias Katsadouros, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Helen Vassalou, Efstathios Kastritis, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 4038.

https://doi.org/10.1182/blood-2025-4038

Published: 2025

Journal Articles

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group

Evangelos Terpos, Efstathios Kastritis, Sosana Delimpasi, Maria Papathanasiou, Vasiliki Lampropoulou, Nikolaos Kanellias, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Evangelos Eleutherakis-Papaiakovou, Yagnik Vyas, Maria Kotsopoulou, Eirini Katodrytou, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 4036.

https://doi.org/10.1182/blood-2025-4036

Published: 2025

Journal Articles

Novel criteria for evaluating early treatment response with whole body magnetic resonance imaging and prognostic implications in patients with newly diagnosed multiple myeloma

Ioannis Ntanasis-Stathopoulos, Vassilis Koutoulidis, Maria Gavriatopoulou, Maria Douka, Panagiotis Malandrakis, Charalampos Filippatos, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Ilias Katsadouros, Eirini Solia, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Lia-Angela Moulopoulos, Meletios Dimopoulos, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 5765.

https://doi.org/10.1182/blood-2025-5765

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) combined with frailty index offer an improved stratification system for transplant-ineligible newly diagnosed multiple myeloma patients

Blood (2025) 146 (Supplement 1): 5791.

https://doi.org/10.1182/blood-2025-5791

Published: 2025

Journal Articles

Impact of immunoglobulin supplementation on infection rates in myeloma patients receiving novel immunotherapies

Blood (2025) 146 (Supplement 1): 3999.

https://doi.org/10.1182/blood-2025-3999

Published: 2025

Journal Articles

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Evangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V. Kostopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Vasiliki Spiliopoulou, Magdalini Migkou, Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos

Blood (2025) 145 (20): 2353–2360.

https://doi.org/10.1182/blood.2024027686

Published: 2025

Journal Articles

Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia Treated with Different Regimens in the Real-World Setting

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Charalampos Filippatos, Magdalini Migkou, Panagiotis Malandrakis, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2024-202610

Published: 2024

Journal Articles

Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients

Meletios-Athanasios Dimopoulos, Despina Fotiou, Foteini Theodorakakou, Irene Solia, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Erasmia Psimenou, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 1948.

https://doi.org/10.1182/blood-2024-203910

Published: 2024

Journal Articles

Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

Efstathios Kastritis, Despina Fotiou, Foteini Theodorakakou, Irene Solia, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 7021.

https://doi.org/10.1182/blood-2024-203941

Published: 2024

Journal Articles

Prognostic Impact of T(11;14) in Newly Diagnosed Patients with Multiple Myeloma in the Era of Modern Treatments

Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, Panagiotis Malandrakis, Alexandros Briasoulis, Charalampos Filippatos, Despina Fotiou, Magdalini Migkou, Vasiliki Spiliopoulou, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 6968.

https://doi.org/10.1182/blood-2024-202627

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma

Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens

Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies

Characteristics and clinical course of younger Patients with early lesions in a contemporary cohort of 1240 patients: Low risk features and low risk of complications

Management and long-term hematologic and neurologic outcomes of IgM-related neuropathy: A single center experience

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

The novel ims / IMWG high-risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis

Efficacy and safety of recombinant adjuvanted zoster vaccine in patients with monoclonal gammopathies: A prospective study

Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Study

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group

Novel criteria for evaluating early treatment response with whole body magnetic resonance imaging and prognostic implications in patients with newly diagnosed multiple myeloma

Circulating tumor cells (CTCs) combined with frailty index offer an improved stratification system for transplant-ineligible newly diagnosed multiple myeloma patients

Impact of immunoglobulin supplementation on infection rates in myeloma patients receiving novel immunotherapies

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia Treated with Different Regimens in the Real-World Setting

Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients

Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

Prognostic Impact of T(11;14) in Newly Diagnosed Patients with Multiple Myeloma in the Era of Modern Treatments

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only